DDrare: Database of Drug Development for Rare Diseases

89. リンパ脈管筋腫症
［臨床試験数：38，薬物数：42（DrugBank：19），標的遺伝子数：26，標的パスウェイ数：134］

Searched query = "Lymphangioleiomyomatosis", "LAM"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 68Ga-NEB; Afinitor; Afinitor 5mg Tablets; Albuterol; Albuterol inhaler; Albuterol nebulizer; Bevacizumab; Celecoxib; Cetuximab; Doxycycline; Doxycycline 100 mg Capsules; EVEROLIMUS; Everolimus; Everolimus (RAD001); Everolimus Oral Product; Glutamine; Hydroxychloroquine; Imatinib; Imatinib Mesylate 400Mg Capsule; Letrozole; Nintedanib; Octreotide; Ofev; Other: Laboratory Biomarker Analysis; Other: Pharmacological Study; PFT; Procedure: PFT; RAD001; RAD001 5mg; Rapamycin; Rapamycin, sirolimus; Resveratrol; Saracatinib; Simvastatin; Sirolimus; Sirolimus Oral Product; Sirolimus and Hydroxychloroquine 200 mg; Sirolimus and Hydroxychloroquine 400 mg; Srolimus; Temsirolimus; Valproic Acid; Valproic acid

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03253913 (ClinicalTrials.gov)	March 31, 2018	10/8/2017	Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial	Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)	Lymphangioleiomyomatosis	Drug: Sirolimus;Drug: Resveratrol	University of Cincinnati	National Heart, Lung, and Blood Institute (NHLBI)	Unknown status	18 Years	N/A	Female	25	Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT03253913
(ClinicalTrials.gov)

March 31, 2018

10/8/2017

Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial

Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)

Lymphangioleiomyomatosis

Drug: Sirolimus;Drug: Resveratrol

University of Cincinnati

National Heart, Lung, and Blood Institute (NHLBI)

Unknown status

18 Years

N/A

Female

Phase 2

United States